Rainmed Medical Technology Co., Ltd.

Rainmed Medical Group was founded in 2014 and is a national high-tech enterprise. The company aims to become a globally leading vascular interventional surgical robot company, currently focusing on the design, R&D and commercialization of core robotic digital functional diagnostic module products: the coronary angiography fractional flow reserve (caFFR) system, the coronary angiography index of microcirculatory resistance (caIMR) system, and the FlashBot vascular interventional surgical robot. Rainmed Medical has gradually built a global R&D, production, sales and service network. The company actively collaborates with top medical centers and experts at home and abroad, has built a comprehensive patent system, and has published multiple research results in authoritative journals such as Cardiovascular Research and JACC: Cardiovascular Interventions. It has signed strategic cooperation agreements with several top domestic medical device distribution service platforms, established a strict quality inspection system and complete supply process, and passed medical device quality management system certification.

Rainmed Medical Group was founded in 2014 and is a national high-tech enterprise. The company was founded with the overall plan of vascular interventional diagnostic and therapeutic surgical robots, and started R&D of digital functional diagnostic modules and automated interventional angiography modules. In 2015, an animal laboratory was built and the first animal experiment of the digital functional diagnostic module was completed at Hebei University laboratory. In 2018, the confirmatory clinical trial of the caFFR system was launched and subject enrollment was completed in December. In 2019, the caFFR system, a coronary stenosis diagnostic product in the digital functional diagnostic module, obtained China NMPA marketing approval and EU CE certification. In 2020, caIMR, another product of the digital functional diagnostic module for microcirculatory lesion diagnosis, entered the scientific clinical validation stage. In 2021, Rainmed Medical was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2297.HK). In 2022, the caIMR system entered the National Medical Products Administration's special approval channel for innovative medical devices. In 2023, the world's first non-interventional coronary microcirculation diagnostic product caIMR obtained China NMPA marketing approval. The company has gradually built a global R&D, production, sales and service network.

• 闪影caFFR系统

  Coronary angiography fractional flow reserve system, a core product of the robotic digital functional diagnostic module.

• 闪影caIMR系统

  Coronary angiography index of microcirculatory resistance system, a core product of the robotic digital functional diagnostic module.

• FlashBot血管介入手术机器人

  Vascular interventional surgical robot.

• 术巧可调弯导管

  A steerable catheter that can autonomously adjust the distal bending degree, suitable for providing access for vascular diagnostic and therapeutic instruments, and for injecting contrast agents and therapeutic drugs. It features 200° stepless distal bending with automatic locking, multi-purpose use, wide application for coronary and peripheral vessels, and larger inner lumen.

1. 1润迈德医疗_caFFR_caIMR_血管介入手术机器人rainmed.com
2. 2润迈德医疗_caFFR_caIMR_血管介入手术机器人rainmed.com
3. 3术巧可调弯导管_润迈德医疗_caFFR_caIMR_血管介入手术机器人rainmed.com
4. 4公司简介_润迈德医疗_caFFR_caIMR_血管介入手术机器人rainmed.com
5. 5苏州润迈德医疗科技有限公司wikidata.org